Citations (73)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Brian Tomlinson, Yan-Hong Li & Paul Chan. (2022) Evaluating gliclazide for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 23:17, pages 1869-1877.
Read now
Read now
Brian Tomlinson, Nivritti Gajanan Patil, Manson Fok, Paul Chan & Christopher Wai Kei Lam. (2022) The role of sulfonylureas in the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 23:3, pages 387-403.
Read now
Read now
André J Scheen. (2020) Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Expert Opinion on Drug Safety 19:3, pages 243-256.
Read now
Read now
Pierre Delanaye & André J. Scheen. (2019) Preventing and treating kidney disease in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 20:3, pages 277-294.
Read now
Read now
Cheli Melzer-Cohen, Avraham Karasik, Philipp J. Leuschner, Joseph Azuri, Varda Shalev & Gabriel Chodick. (2018) Dose adjustment of metformin and dipeptidyl-peptidase IV inhibitors in diabetic patients with renal dysfunction. Current Medical Research and Opinion 34:10, pages 1849-1854.
Read now
Read now
Andrea Corsonello, Sergio Fusco, Silvia Bustacchini, Carlos Chiatti, Raffaella Moresi, Anna Rita Bonfigli, Giuseppina Di Stefano & Fabrizia Lattanzio. (2016) Special considerations for the treatment of chronic kidney disease in the elderly. Expert Review of Clinical Pharmacology 9:5, pages 727-737.
Read now
Read now
Baptist Gallwitz. (2015) Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin. Therapeutics and Clinical Risk Management 11, pages 799-805.
Read now
Read now
André J. Scheen. (2015) SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opinion on Drug Safety 14:12, pages 1879-1904.
Read now
Read now
André J Scheen. (2015) Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety 14:4, pages 505-524.
Read now
Read now
André J Scheen. (2015) A review of gliptins for 2014. Expert Opinion on Pharmacotherapy 16:1, pages 43-62.
Read now
Read now
Malcolm A. Young, Jeffrey A. Wald, Jessica E. Matthews, Rhona Scott, Rebecca J. Hodge, Hui Zhi & Rickey R. Reinhardt. (2014) Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist. Postgraduate Medicine 126:7, pages 84-97.
Read now
Read now
André J Scheen. (2014) Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 839-857.
Read now
Read now
Malcolm A. Young, Jeffrey A. Wald, Jessica E. Matthews, Fred Yang & Rickey R. Reinhardt. (2014) Effect of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Albiglutide. Postgraduate Medicine 126:3, pages 35-46.
Read now
Read now
André J Scheen. (2014) Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opinion on Drug Metabolism & Toxicology 10:5, pages 647-663.
Read now
Read now
Articles from other publishers (59)
Jeremy Gilbert, Phil McFarlane, James Kim, Susie Jin, Peter Senior, Jeremy Gilbert, Harpreet S. Bajaj, Susie Jin, James Kim, Harpreet S. Bajaj, Jeremy Gilbert, Robyn Houlden, James Kim, Barbara MacDonald, Dylan MacKay, Kerry Mansell, Doreen Rabi, Diana Sherifali & Peter Senior. (2023) Use of Classes of Antihyperglycemic Agents in People With Type 2 Diabetes Based on Level of Estimated Glomerular Filtration Rate. Canadian Journal of Diabetes 47:3, pages 223-227.
Crossref
Crossref
Andrea Corsonello, Antonello Rocca, Carmela Lo Russo & Luca Soraci. 2023. Optimizing Pharmacotherapy in Older Patients. Optimizing Pharmacotherapy in Older Patients
405
426
.
Sidra Jamil, Arfa Zainab, Avneet Kaur Manjeet Singh Arora, Tanveer Ahamad Shaik, Vimal Khemani, Favour C Mekowulu, Yared N Aschalew & Saima Khan. (2022) Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients With Diabetes and Chronic Kidney Disease (CKD): A Meta-analysis of Randomized Control Trials. Cureus.
Crossref
Crossref
Lucia Brodosi, Salvatore Petta, Maria L. Petroni, Giulio Marchesini & Maria C. Morelli. (2021) Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients. Transplantation 106:3, pages 462-478.
Crossref
Crossref
Yan Liu, Chanyue Zhao, Xiaofen Xiong, Ming Yang & Lin Sun. (2021) Insulin therapy in diabetic kidney disease. Diabetic Nephropathy 1:2, pages 67-76.
Crossref
Crossref
Sandro Gentile, Ersilia Satta, Felice Strollo, Giuseppina Guarino, Carmine Romano, Teresa Della Corte & Carmelo Alfarone. (2021) Insulin-induced skin lipohypertrophies: A neglected cause of hypoglycemia in dialysed individuals with diabetes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15:4, pages 102145.
Crossref
Crossref
Antoine Christiaens, Benoit Boland, Marie Germanidis, Olivia Dalleur & Séverine Henrard. (2020) Poor health status, inappropriate glucose-lowering therapy and high one-year mortality in geriatric patients with type 2 diabetes. BMC Geriatrics 20:1.
Crossref
Crossref
André J. Scheen. (2020) Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease. Clinical Pharmacokinetics 59:8, pages 981-994.
Crossref
Crossref
. (2020) Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD). Revista Española de Cardiología 73:5, pages 404.e1-404.e59.
Crossref
Crossref
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen, Heikki V Huikuri, Isabelle Johansson, Peter Jüni, Maddalena Lettino, Nikolaus Marx, Linda G Mellbin, Carl J Östgren, Bianca Rocca, Marco Roffi, Naveed Sattar, Petar M Seferović, Miguel Sousa-Uva, Paul Valensi, David C Wheeler, Massimo Francesco Piepoli, Kåre I Birkeland, Stamatis Adamopoulos, Ramzi Ajjan, Angelo Avogaro, Colin Baigent, Marianne Brodmann, Héctor Bueno, Claudio Ceconi, Ovidiu Chioncel, Andrew Coats, Jean-Philippe Collet, Peter Collins, Bernard Cosyns, Carlo Di Mario, Miles Fisher, Donna Fitzsimons, Sigrun Halvorsen, Dominique Hansen, Arno Hoes, Richard I G Holt, Philip Home, Hugo A Katus, Kamlesh Khunti, Michel Komajda, Ekaterini Lambrinou, Ulf Landmesser, Basil S Lewis, Cecilia Linde, Roberto Lorusso, François Mach, Christian Mueller, Franz-Josef Neumann, Frederik Persson, Steffen E Petersen, Anna Sonia Petronio, Dimitrios J Richter, Giuseppe M C Rosano, Peter Rossing, Lars Rydén, Evgeny Shlyakhto, Iain A Simpson, Rhian M Touyz, William Wijns, Matthias Wilhelm, Bryan Williams, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen, Heikki V Huikuri, Isabelle Johansson, Peter Jüni, Maddalena Lettino, Nikolaus Marx, Linda G Mellbin, Carl J Östgren, Bianca Rocca, Marco Roffi, Naveed Sattar, Petar M Seferović, Miguel Sousa-Uva, Paul Valensi, David C Wheeler, Stephan Windecker, Victor Aboyans, Colin Baigent, Jean-Philippe Collet, Veronica Dean, Victoria Delgado, Donna Fitzsimons, Chris P Gale, Diederick E Grobbee, Sigrun Halvorsen, Gerhard Hindricks, Bernard Iung, Peter Jüni, Hugo A Katus, Ulf Landmesser, Christophe Leclercq, Maddalena Lettino, Basil S Lewis, Bela Merkely, Christian Mueller, Steffen E Petersen, Anna Sonia Petronio, Dimitrios J Richter, Marco Roffi, Evgeny Shlyakhto, Iain A Simpson, Miguel Sousa-Uva, Rhian M Touyz, Parounak H Zelveian, Daniel Scherr, Tofig Jahangirov, Irina Lazareva, Bharati Shivalkar, Nabil Naser, Ivan Gruev, Davor Milicic, Petros M Petrou, Aleš Linhart, Per Hildebrandt, Hosam Hasan-Ali, Toomas Marandi, Seppo Lehto, Jacques Mansourati, Ramaz Kurashvili, Gerasimos Siasos, Csaba Lengyel, Inga S Thrainsdottir, Doron Aronson, Andrea Di Lenarda, Aigul Raissova, Pranvera Ibrahimi, Saamai Abilova, Karlis Trusinskis, Georges Saade, Hisham Benlamin, Zaneta Petrulioniene, Cristiana Banu, Caroline Jane Magri, Lilia David, Aneta Boskovic, Mohamed Alami, An Ho Liem, Marijan Bosevski, Gard Frodahl Tveitevaag Svingen, Marianna Janion, Cristina Gavina, Dragos Vinereanu, Sergey Nedogoda, Tatiana Mancini, Marina Deljanin Ilic, Lubomira Fabryova, Zlatko Fras, Manuel F Jiménez-Navarro, Anna Norhammar, Roger Lehmann, Mohamed Sami Mourali, Dilek Ural, Elena Nesukay & Tahseen Ahmad Chowdhury. (2020) 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal 41:2, pages 255-323.
Crossref
Crossref
Sebastian Niezen, Humberto Diaz del Castillo, Lumen A. Mendez Castaner & Alessia Fornoni. (2019) Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease. Endocrinology, Diabetes & Metabolism 2:3.
Crossref
Crossref
. 2019. Demystifying Drug Dosing in Renal Dysfunction. Demystifying Drug Dosing in Renal Dysfunction
249
263
.
A.J. Scheen. (2019) Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. Diabetes & Metabolism 45:2, pages 110-121.
Crossref
Crossref
Deborah A. Chon, Rachael T. Oxman, Rashmi S. Mullur & Jane Eileen Weinreb. 2019. Endocrine Disorders in Kidney Disease. Endocrine Disorders in Kidney Disease
49
74
.
Marcel H A Muskiet, David C Wheeler & Hiddo J L Heerspink. (2018) New pharmacological strategies for protecting kidney function in type 2 diabetes. The Lancet Diabetes & Endocrinology.
Crossref
Crossref
D. Szukiewicz, Grzegorz Szewczyk, Michal Pyzlak, Aleksandra Stangret, Michal Bachanek, Seweryn Trojanowski, Habib Alkhalayla & Jaroslaw Wejman. (2018) Anti-inflammatory Action of Metformin with Respect to CX3CL1/CX3CR1 Signaling in Human Placental Circulation in Normal-Glucose Versus High-Glucose Environments. Inflammation 41:6, pages 2246-2264.
Crossref
Crossref
Stephen Colagiuri, David Matthews, Lawrence A. Leiter, Siew Pheng Chan, Giorgio Sesti & Michel Marre. (2018) The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes Research and Clinical Practice 143, pages 1-14.
Crossref
Crossref
Caterina Conte & Antonio Secchi. (2018) Post-transplantation diabetes in kidney transplant recipients: an update on management and prevention. Acta Diabetologica 55:8, pages 763-779.
Crossref
Crossref
Jan Vachek, Oskar Zakiyanov & Vladimír Tesař. (2018) Novel antidiabetics and progression of diabetic nephropathy. Interní medicína pro praxi 20:1, pages 24-26.
Crossref
Crossref
A.J. Scheen & P. Delanaye. (2018) Renal outcomes with dipeptidyl peptidase-4 inhibitors. Diabetes & Metabolism 44:2, pages 101-111.
Crossref
Crossref
Roberto Trevisan. (2017) The Role of Vildagliptin in the Therapy of Type 2 Diabetic Patients with Renal Dysfunction. Diabetes Therapy 8:6, pages 1215-1226.
Crossref
Crossref
Rajesh Rajput, Binayak Sinha, Sujoy Majumdar, M. Shunmugavelu & Sarita Bajaj. (2017) Consensus statement on insulin therapy in chronic kidney disease. Diabetes Research and Clinical Practice 127, pages 10-20.
Crossref
Crossref
Tahseen A. Chowdhury, Danushan Srirathan, Georgi Abraham, Elizabeth L. Oei, Stanley L. Fan, Kieran McCafferty & M. Magdi Yaqoob. (2017) Could metformin be used in patients with diabetes and advanced chronic kidney disease?. Diabetes, Obesity and Metabolism 19:2, pages 156-161.
Crossref
Crossref
Sara Dominijanni, Silvia Cipriani, Moreno Malaguti, Luigi Triolo, Ferruccio Ansali & Fulvio Floccari. (2017) Antidiabetic Medication in Patients with Chronic Kidney Disease: What's New?. Nephrology @ Point of Care 3:1, pages napoc.5000210.
Crossref
Crossref
P. Sneha & C. George Priya Doss. (2016) Gliptins in managing diabetes - Reviewing computational strategy. Life Sciences 166, pages 108-120.
Crossref
Crossref
Abd A. Tahrani, Anthony H. Barnett & Clifford J. Bailey. (2016) Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nature Reviews Endocrinology 12:10, pages 566-592.
Crossref
Crossref
Merlin C. Thomas, Päivi M. Paldánius, Rajeev Ayyagari, Siew Hwa Ong & Per-Henrik Groop. (2016) Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. Diabetes Therapy 7:3, pages 439-454.
Crossref
Crossref
Jennifer J. Wright & Tracy S. Tylee. (2016) Pharmacologic Therapy of Type 2 Diabetes. Medical Clinics of North America 100:4, pages 647-663.
Crossref
Crossref
A. Oishi, Noriko Makita, K. Manaka, K. Mitani, H. Tomita & T. Iiri. (2015) Successful glycemic control with three times a week degludec injection by medical staff for an elderly hemodialysis patient with type 2 diabetes. Diabetology International 7:1, pages 95-99.
Crossref
Crossref
Nanette C. Schloot, Axel Haupt, Morten Schütt, Klaus Badenhoop, Markus Laimer, Claudia Nicolay, Matthew Reaney, Katharina Fink & Reinhard W. Holl. (2016) Risk of severe hypoglycemia in sulfonylurea-treated patients from diabetes centers in Germany/Austria: How big is the problem? Which patients are at risk?. Diabetes/Metabolism Research and Reviews 32:3, pages 316-324.
Crossref
Crossref
Antoine Bouquegneau, Emmanuelle Vidal-Petiot, Olivier Moranne, Christophe Mariat, Jean-Jacques Boffa, Fran?ois Vrtovsnik, Andr?-Jean Scheen, Jean-Marie Krzesinski, Martin Flamant & Pierre Delanaye. (2016) Creatinine-based equations for the adjustment of drug dosage in an obese population. British Journal of Clinical Pharmacology 81:2, pages 349-361.
Crossref
Crossref
Carolyn F Deacon. 2016. Handbook of Incretin-based Therapies in Type 2 Diabetes. Handbook of Incretin-based Therapies in Type 2 Diabetes
45
60
.
Joshua J. Neumiller & Irl B. Hirsch. (2015) Management of Hyperglycemia in Diabetic Kidney Disease. Diabetes Spectrum 28:3, pages 214-219.
Crossref
Crossref
Janice M.S. LopezRobert A. BaileyMarcia F.T. Rupnow. (2015) Demographic Disparities Among Medicare Beneficiaries with Type 2 Diabetes Mellitus in 2011: Diabetes Prevalence, Comorbidities, and Hypoglycemia Events. Population Health Management 18:4, pages 283-289.
Crossref
Crossref
André J. Scheen. (2015) Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Clinical Pharmacokinetics 54:7, pages 691-708.
Crossref
Crossref
Andr? J Scheen. (2015) Metformin should not be contraindicated in patients with type 2 diabetes and mild to moderate renal impairment. Evidence Based Medicine 20:3, pages 115-115.
Crossref
Crossref
Antonios Douros, Natalie Ebert, Olga Jakob, Peter Martus, Reinhold Kreutz & Elke Schaeffner. (2015) Estimating kidney function and use of oral antidiabetic drugs in elderly. Fundamental & Clinical Pharmacology 29:3, pages 321-328.
Crossref
Crossref
Mazen Alsahli & John Gerich. (2015) Hypoglycemia in Patients with Diabetes and Renal Disease. Journal of Clinical Medicine 4:5, pages 948-964.
Crossref
Crossref
A.-J. Scheen. (2015) Antidiabétiques oraux dans le traitement du diabète de type 2 : perspectives historique et médico-économique. Médecine des Maladies Métaboliques 9:2, pages 186-197.
Crossref
Crossref
A. Avogaro, A. Dardano, S. V. de Kreutzenberg & S. Del Prato. (2015) Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes. Diabetes, Obesity and Metabolism 17:2, pages 107-115.
Crossref
Crossref
André J. Scheen. (2014) Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Drugs 75:1, pages 33-59.
Crossref
Crossref
André J. Scheen. (2014) Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes. Clinical Pharmacokinetics 54:1, pages 1-21.
Crossref
Crossref
Mazen Alsahli & John E. Gerich. (2014) Hypoglycemia, Chronic Kidney Disease, and Diabetes Mellitus. Mayo Clinic Proceedings 89:11, pages 1564-1571.
Crossref
Crossref
Katherine R. Tuttle, George L. BakrisRudolf W. BilousJane L. Chiang, Ian H. de Boer, Jordi Goldstein-Fuchs, Irl B. Hirsch, Kamyar Kalantar-Zadeh, Andrew S. Narva, Sankar D. Navaneethan, Joshua J. Neumiller, Uptal D. PatelRobert E. Ratner, Adam T. Whaley-Connell & Mark E. Molitch. (2014) Diabetic Kidney Disease: A Report From an ADA Consensus Conference. Diabetes Care 37:10, pages 2864-2883.
Crossref
Crossref
Katherine R. Tuttle, George L. Bakris, Rudolf W. Bilous, Jane L. Chiang, Ian H. de Boer, Jordi Goldstein-Fuchs, Irl B. Hirsch, Kamyar Kalantar-Zadeh, Andrew S. Narva, Sankar D. Navaneethan, Joshua J. Neumiller, Uptal D. Patel, Robert E. Ratner, Adam T. Whaley-Connell & Mark E. Molitch. (2014) Diabetic Kidney Disease: A Report From an ADA Consensus Conference. American Journal of Kidney Diseases 64:4, pages 510-533.
Crossref
Crossref
. (2014) Pharmacokinetic drug interactions are unlikely when sodium–glucose cotransporters type 2 inhibitors are used to treat type 2 diabetes mellitus. Drugs & Therapy Perspectives 30:10, pages 363-366.
Crossref
Crossref
Hanne Haahr & Tim Heise. (2014) A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance. Clinical Pharmacokinetics 53:9, pages 787-800.
Crossref
Crossref
André J. Scheen. (2014) Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus. Clinical Pharmacokinetics 53:9, pages 773-785.
Crossref
Crossref
P. Arnouts, D. Bolignano, I. Nistor, H. Bilo, L. Gnudi, J. Heaf & W. v. Biesen. (2013) Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. Nephrology Dialysis Transplantation 29:7, pages 1284-1300.
Crossref
Crossref
Miyako Kishimoto & Mitsuhiko Noda. (2014) Glucose management in diabetic patients undergoing hemodialysis. Diabetology International 5:2, pages 84-91.
Crossref
Crossref
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle & Uli C Broedl. (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology 2:5, pages 369-384.
Crossref
Crossref
Richard E. Gilbert. (2014) The perils of clinical trials. Kidney International 85:4, pages 745-747.
Crossref
Crossref
André J. Scheen. (2014) Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus. Clinical Pharmacokinetics 53:4, pages 295-304.
Crossref
Crossref
André J. Scheen. (2014) Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor. Clinical Pharmacokinetics 53:3, pages 213-225.
Crossref
Crossref
Istv?n Kiss, Gerhard Arold, Carsten Roepstorff, Susanne Gammelgaard B?ttcher, S?ren Klim & Hanne Haahr. (2013) Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment. Clinical Pharmacokinetics 53:2, pages 175-183.
Crossref
Crossref
André J Scheen. (2013) SGLT2 versus DPP4 inhibitors for type 2 diabetes. The Lancet Diabetes & Endocrinology 1:3, pages 168-170.
Crossref
Crossref
Serge Halimi. (2013) Prise en charge du diabète de type 2 : anciens ou nouveaux médicaments, comment choisir ?. La Presse Médicale 42:5, pages 861-870.
Crossref
Crossref
A.J. Scheen & N. Paquot. (2013) Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes. Diabetes & Metabolism 39:3, pages 179-190.
Crossref
Crossref
Jennifer M. Hackel. (2013) ‘Patient-Centered Care’ for Complex Patients with Type 2 Diabetes Mellitus–-Analysis of Two Cases. Clinical Medicine Insights: Endocrinology and Diabetes 6, pages CMED.S12231.
Crossref
Crossref